» Articles » PMID: 16472711

Goals of Treatment for Patients with Metastatic Breast Cancer

Overview
Journal Semin Oncol
Specialty Oncology
Date 2006 Feb 14
PMID 16472711
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The key goal in the treatment of metastatic breast cancer is to prolong survival, with an emphasis on restricting treatment-related toxicity as much as possible. Despite the plethora of treatment modalities available in metastatic breast cancer, significant survival differences are relatively uncommon. Symptom relief and quality of life are other important, clinically validated measurement instruments. Symptom relief in particular is not used as widely used as it could be, in contrast to lung cancer where it has been proven clinically informative. Finally, time to disease progression is an increasingly used primary endpoint in comparing treatments for metastatic breast cancer; this measure includes both patients who achieve an objective response, and those whose disease may be stabilized with treatment.

Citing Articles

A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer.

McGehee C, Mori Y NPJ Syst Biol Appl. 2024; 10(1):140.

PMID: 39614108 PMC: 11607384. DOI: 10.1038/s41540-024-00461-2.


Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities-A State-of-the-Art Review.

Kunachowicz D, Klosowska K, Sobczak N, Kepinska M Nanomaterials (Basel). 2024; 14(17).

PMID: 39269086 PMC: 11396817. DOI: 10.3390/nano14171424.


The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study.

Al-Ziftawi N, Elazzazy S, Alam M, Shafie A, Hamad A, Bbujassoum S Front Oncol. 2024; 13:1203684.

PMID: 38162489 PMC: 10757634. DOI: 10.3389/fonc.2023.1203684.


Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy.

Schlefman J, Brenin C, Millard T, Dillon P Med Oncol. 2023; 41(1):19.

PMID: 38103078 DOI: 10.1007/s12032-023-02255-8.


Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.

Engel-Nitz N, Johnson M, Johnson M, Cha-Silva A, Kurosky S, Liu X Patient Prefer Adherence. 2023; 17:1049-1062.

PMID: 37096162 PMC: 10122484. DOI: 10.2147/PPA.S401480.